We Offer Worldwide Shipping
Login Wishlist

Chenodesoxycholic acid

$43

  • Brand : BIOFRON

  • Catalogue Number : BF-C2023

  • Specification : 98%

  • CAS number : 474-25-9

  • Formula : C24H40O4

  • Molecular Weight : 392.58

  • PUBCHEM ID : 10133

  • Volume : 20mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BF-C2023

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

2-8°C

Molecular Weight

392.58

Appearance

White crystalline powder

Botanical Source

Anser cygnoides orientalis

Structure Type

Others

Category

Standards;Natural Pytochemical;API

SMILES

CC(CCC(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C

Synonyms

CDCA/Chenix/Chenodex/Hekbilin/Fluibil/Ulmenide/Chenocol/chendol/Kebilis/anthropododesoxycholicacid/Chenodeoxycholic acid/3α,7α-Dihydroxy-5β-cholanic Acid/Chendiol/5β-Cholanic Acid-3α,7α-diol

IUPAC Name

(4R)-4-[(3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid

Density

1.1±0.1 g/cm3

Solubility

Methanol; Dioxane; DMSO

Flash Point

298.8±19.7 °C

Boiling Point

547.1±25.0 °C at 760 mmHg

Melting Point

165-167 °C(lit.)

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

2918190000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:474-25-9) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

PMID

27406083

Abstract

Obeticholic acid (Ocaliva(TM)) is a farnesoid-X receptor (FXR) agonist that is being developed by Intercept Pharmaceuticals for the treatment of various liver diseases, and has recently been granted accelerated approval in the USA for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid, or as monotherapy in adults unable to tolerate ursodeoxycholic acid. The drug is in preregistration for this indication in the EU. This article summarizes the milestones in the development of obeticholic acid leading to this first approval for primary biliary cholangitis.

Title

Obeticholic Acid: First Global Approval

Author

A Markham 1 , Susan J Keam 2

Publish date

2016 Aug

PMID

31201552

Abstract

Obeticholic acid (OCA), 6α-ethyl-3α,7α-dihydroxy-5-cholan-24-oic acid, is a semisynthetic derivative of the chenodeoxycholic acid (CDCA, 3α,7α-dihydroxy-5-cholan-24-oic acid), a relatively hydrophobic primary bile acid synthesized in the liver from cholesterol. OCA, also known as 6-ethyl-CDCA or INT-747, was originally described by investigators at the Perugia University in 2002 as a selective ligand for the bile acid sensor, farnesoid-X-receptor (FXR). In addition to FXR and similarly to CDCA, OCA also activates GPBAR1/TGR5, a cell membrane G protein-coupled receptor for secondary bile acids. In 2016, based on the results of phase II studies showing efficacy in reducing the plasma levels of alkaline phosphatase, a surrogate biomarker for disease progression in primary biliary cholangitis (PBC), OCA has gained approval as a second-line treatment for PBC patients nonresponsive to UDCA. The use of OCA in PBC patients associates with several side effects, the most common of which is pruritus, whose incidence is dose-dependent and is extremely high when this agent is used as a monotherapy. Additionally, the use of OCA associates with the increased risk for the development of liver failure in cirrhotic PBC patients. Currently, OCA is investigated for its potential in the treatment of nonalcoholic steatohepatitis (NASH). Phase II and III trials have shown that OCA might attenuate the severity of liver fibrosis in patients with NASH, but it has no efficacy in reversing the steatotic component of the disease, while reduces the circulating levels of HDL-C and increases LDL-C. In summary, OCA has been the first-in-class of FXR ligands advanced to a clinical stage and is now entering its third decade of life, highlighting the potential benefits and risk linked to FXR-targeted therapies.

KEYWORDS

FXR; GPBAR1; Nonalcoholic steatohepatitis (NASH); Obeticholic acid; Primary biliary cholangitis (PBC); Side effects.

Title

Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders

Author

Stefano Fiorucci 1 2 , Cristina Di Giorgio 3 , Eleonora Distrutti 4

Publish date

2019

PMID

31813639

Abstract

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.

Title

Obeticholic Acid: Towards First Approval for NASH

Author

Mohammed Eslam 1 , Rino Alvani 2 , Gamal Shiha 3

Publish date

2019 Dec 14


Description :

Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.